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324 The cystic ﬁbrosis annual review − a need to update the
guidance?
D. Nazareth1, M.E. Phitidis1, H.G. Tan1, M.J. Ledson1, M.J. Walshaw1,
J. Greenwood1. 1Liverpool Heart and Chest Hospital, Liverpool, United Kingdom
Introduction: CF care requires the monitoring and treatment of a number of organ
systems. To aid this, a detailed assessment of all aspects of the CF patient’s condition
(the annual review, AR) is recommended, but published guidance is 9 years old.
The AR content in our adult unit has evolved considerably over recent years. We
wished to assess AR use in the UK with a view to informing best practice.
Method: We surveyed 43 specialist CF centres (18 adult, 25 paediatric) about their
AR practice.
Results: The AR is supervised by a CF specialist nurse in 21 centres (49%) and a
consultant in 17 (39%), usually timed around the patient’s birthday. 27 (63%) hold
a speciﬁc AR clinic. All centres perform full blood count, renal and liver function
tests, vitamin assays, spirometry and a chest X-ray: other elements are shown in
the Table. Only half of ARs are discussed at a speciﬁc MDT meeting, with a report
generated in 13 adult (72%) and 23 (92%) paediatric centres.
Annual Review investigations
Investigation performed Adult units
(n = 18)
Paediatric units
(n = 25)
c2 p
CXR − Northern Score 6 21 11.49 <0.01
Abdominal USS 11 25 11.61 <0.01
Arterial blood gases 4 0 6.12 <0.02
Urine dipstick 2 8 2.55 NS
HBA1c 15 21 0.003 NS
Sputum analysis 18 23 1.51 NS
Immunoglobulins 11 22 4.23 <0.05
Aspergillus serology 17 23 0.09 NS
Pseudomonas serology 12 12 1.47 NS
Conclusion: AR practice in the UK is variable, and there are differences between
the adult and paediatric sectors. There is a need to develop speciﬁc AR guidelines
for adult and paediatric centres in order to standardise the process.
325 What role do the general practitioners (GP) have in the care of
cystic ﬁbrosis (CF) patients?
S. Huq1, S. Kalidindi1, S. Sureshkumar1, S. Chandramouli1, J. Greenwood1,
M.J. Walshaw1. 1Liverpool Heart and Chest Hospital NHS Foundation Trust,
Liverpool, United Kingdom
Introduction: Although the majority of care for CF patients is provided by specialist
CF units, GPs can play a vital role in their overall holistic care. The aim of this
study was to identify the various aspects of GPs involvement in the care of adult
CF patients.
Methods: Using a structured questionnaire, we surveyed 92 consecutive patients
(mean age 28 yrs [range 18−66], 45 female) attending our large adult unit, asking
about contact with their GP in the previous year.
Results: Although 4 patients never visited their GP, 54% visited 1−2 times, 27%
3−5 times, 7% 6−10 times, and 8% more frequently in the last one year. The
commonest reason (28%) was to obtain repeat prescriptions followed by coughs/
colds (22%), vaccination (9%), psychological issues (5%), contraception (5%), skin
(5%) and musculoskeletal problems (5%) and cervical smear (4%). Other reasons
include abdominal, ear and eye problems and UTI. Common medications given by
GP were contraceptives, antibiotics, antidepressants, supplements and analgesics.
When GP started treatment for respiratory infections, follow-up was planned for
only 50%. 75% found it easy to get back-up antibiotics from their GP when needed
and 79% would contact the GP ﬁrst for a non-CF problem. On a scale of 1 (poor)
to 10 (excellent) the average GP rating was 7.71.
Conclusion: Although our cohort of CF patients has a variable degree of interaction
with their GPs, their overall satisfaction was good. GPs have a vital role in the
monitoring of progress, contraception, vaccination, and general health education
for CF patients and can provide additional support to the CF team through regular
feedback, including compliance issues.
326* Incidence and resource utilisation of pulmonary
exacerbations (PE) in patients with cystic ﬁbrosis (CF)
in the UK
J. Bradley1, S. Blume2, M.-M. Balp3, D. Honeybourne4, J.S. Elborn5. 1University
of Ulster, Belfast, United Kingdom; 2United BioSource Corporation, Bethesda,
United States; 3Novartis, Basil, Switzerland; 4Birmingham Heartlands Hospital,
Birmingham, United Kingdom; 5Queens University Belfast, Belfast, United
Kingdom
Objective: To obtain incidence and resource utilisation data for pulmonary exacer-
bations (PE) in adult patients with CF and chronic PA infections.
Methods: A 1 year retrospective chart review in 5 UK hospitals.
Results: Data was collected on 94 patients, 51% male, mean (SD): age 28.5
(8.2) yrs; FEV1 58.7 (26.8) %. The mean no. of exacerbations (either requiring
hospitalisation or treated at home) per patient per year was 3.6. The mean rate
of hospital exacerbations was 1.5 per patient per year and the mean rate of home
treated exacerbations was 2.2 per patient per year. Over half (57%) of patients had
at least 1 exacerbation requiring hospitalisation. 83% of patients had home-treated
exacerbations, with 21% of patients having 1 PE and 62% having multiple PEs. For
the 150 hospital PEs the mean length of stay was 9.2 days per exacerbation. Half of
the stays required home use of intravenous antibiotics (IVAB) after discharge and
almost all (95%) required oral antibiotics. In the 217 home-treated exacerbations
nearly half of the exacerbations (42%) required IVABs and 71% oral antibiotics.
The mean length of IVAB treatment was 7.6 days per exacerbation and the mean
length of oral antibiotics was 10 days per exacerbation.
Conclusion: Pulmonary exacerbations in CF patients with chronic PA infection are
resource-intensive with over 50% of patients hospitalised per annum in the study.
This study was supported by Novartis and preliminary results were presented at the
ERS 2010.
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Despite advances in management and treatment people with cystic ﬁbrosis (CF) still
die at a relatively young age. Although an integral part of the CF multidisciplinary
team’s workload is palliative care, relatively little is known about the end of life
(EOL) issues associated with CF in the UK. Because of the unique circumstances
of CF it is not possible to translate ﬁndings from other life threatening conditions.
I have conducted a study of CF Nurse Specialists (CFNS) in the UK to explore
CF EOL issues in the UK.
This was a qualitative study, comprising a questionnaire to all UK CFNS’s working
within adult centres. 31 UK CFNS’s completed a questionnaire (45% response rate).
The median time in post for respondents was 7 years.
The ﬁndings of this study have highlighted a number of issues. The study reinforces
ﬁndings from previous studies stating that EOL in CF is varied and complex,
especially when the possibility of potential lung transplantation is involved.
Although all respondents felt that early and well-planned EOL discussions were
preferable, only 35% of centres had a planned approach with patients. In 10% of
situations, EOL was not discussed at all and in 32% of situations, it was not
broached until the terminal stage of life. In 94% of situations, the consultant or
CFNS raised EOL issues.
68% of respondents had not had any speciﬁc training in EOL issues in CF and this
is an area that needs to be addressed.
Finally, EOL discussions need to occur on an individual basis, with the patient’s
needs and wishes respected at all time. Further research in this area, including
studies involving patients themselves, is recommended.
